ASO Author Reflections: Immune-Related Adverse Events During Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast Cancer May Influence Time to Adjuvant Radiation

Ann Surg Oncol. 2024 Aug;31(8):5205-5206. doi: 10.1245/s10434-024-15445-z. Epub 2024 May 22.

Authors

Sara P Myers¹, Stephanie M Downs-Canner²

Affiliations

¹ Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. [email protected].

PMID: 38776008
DOI: 10.1245/s10434-024-15445-z

No abstract available

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Female
Humans
Immunotherapy* / adverse effects
Immunotherapy* / methods
Neoadjuvant Therapy*
Prognosis
Radiotherapy, Adjuvant
Time-to-Treatment
Triple Negative Breast Neoplasms* / drug therapy
Triple Negative Breast Neoplasms* / pathology
Triple Negative Breast Neoplasms* / therapy